In evidence synthesis, effect measure modifiers are typically described as variables that induce treatment effect heterogeneity at the individual level, through treatment-covariate interactions in an outcome model. As such, effect modification is defined with respect to a conditional measure. However, marginal effect estimates are required for population-level decisions in health technology assessment. For non-collapsible effect measures, purely prognostic variables that do not predict response to treatment at the individual level may modify marginal treatment effects at the population level. This has important implications for recommended practices for evidence synthesis. Firstly, unadjusted indirect comparisons of marginal effects may be biased in the absence of individual-level treatment effect heterogeneity. Secondly, covariate adjustment may be necessary to account for cross-study imbalances in purely prognostic variables. Popular summary measures in meta-analysis such as odds ratios and hazard ratios are non-collapsible. Collapsible measures would facilitate the transportability of marginal effects between studies by: (1) removing dependence on model-based covariate adjustment when there is treatment effect homogeneity at the individual level; and (2) easing the selection of baseline characteristics for covariate adjustment when there is heterogeneity.
翻译:在证据综合中,效果计量改变者通常被描述为通过结果模型中的治疗-变异相互作用在个人一级诱发治疗效果异化的变量,因此,对效果的修改是按有条件措施加以界定的;然而,在健康技术评估中,对人口一级的决定需要进行边际效应估计;对于非混合效应措施而言,纯粹预测性的变数,不能预测对个人一级治疗的反应,可能改变在人口一级对边际治疗的影响;这对建议的证据综合做法有重要影响。首先,在缺乏个人一级治疗效果异性的情况下,对边际效应的未经调整的间接比较可能偏向于个人一级治疗效果异性。第二,为了计算纯预测变量中交叉研究不平衡的原因,可能需要对效果作复变性调整。对于诸如胜率比率和危险比率等元分析的流行性概括措施是不可重叠的。